Plasma Concentration & Therapeutic Range

Tags:
No items found.

Pharmacology

Summary

The effectiveness of a drug is driven by its concentration at the active site, such as enzymes or cell-membrane receptors, rather than by its dose alone. This principle underscores the importance of the dose-response relationship, which encompasses both pharmacokinetics—involving dose, dosage form, frequency, route of administration, and plasma concentration—and pharmacodynamics, which refers to the relationship between the concentration of a drug in the body and its resulting effects, both therapeutic and adverse. Central to this is the concept of the therapeutic window: the range of drug plasma concentration that yields therapeutic benefits while minimizing adverse effects. Plasma concentrations below the minimum effective concentration (MEC) might result in under-treatment, while those surpassing the maximum tolerated concentration (MTC) heighten the risk of toxicity.

The drug's onset of action is initiated once the MEC is attained. Its duration of action corresponds to the time the drug's plasma concentration remains within the therapeutic range. The frequency of dosing is closely linked to the drug's elimination rate: rapid elimination necessitates more frequent dosing, whereas a slower rate requires less. Administering smaller doses leads to a slower attainment of MEC but ensures the MTC is not surpassed, thereby stabilizing the plasma concentration within the therapeutic window. Conversely, larger doses hasten the achievement of MEC but risk surpassing the MTC, leading to potential toxicity. Some drugs, like digoxin and warfarin, mandate individualized dosing to remain within their therapeutic windows. The therapeutic index is computed by dividing the dose resulting in toxicity for 50% of patients (TD50) by the dose inducing a favorable response in 50% of patients (ED50). In cases where a patient demonstrates a suboptimal response, both potential pharmacokinetic issues and adherence should be evaluated.

Lesson Outline

Don't stop here!

Get access to 133 more Pharmacology lessons & 13 more medical school learning courses with one subscription!

Try 7 Days Free

FAQs

What is the significance of plasma concentration in pharmacokinetics and pharmacodynamics?

Plasma concentration significantly drives the response in the body to a drug and is a crucial component of both pharmacokinetics and pharmacodynamics. It represents the amount of drug circulating in the bloodstream that is able to induce a physiological effect. Pharmacokinetics considers factors such as dose, dosage form, frequency, and route of administration to predict a drug's plasma concentration, whereas pharmacodynamics examines the relationship between the drug's concentration and its effect on the body.

How is the therapeutic range related to plasma concentration?

The therapeutic range, also known as the therapeutic window, is the range of drug plasma concentration that provides a therapeutic effect while minimizing adverse effects and toxicity. A plasma concentration below the minimum effective concentration may result in under-treatment, while a concentration above the maximum tolerated concentration can increase the risk of adverse effects and toxicity. Therefore, effective treatment requires maintaining the drug plasma concentration within this therapeutic range.

What factors influence the onset and duration of action for drugs?

The onset of drug action occurs when the minimum effective concentration (MEC) in plasma is reached. Meanwhile, the drug's duration of action, or the time within which it stays effective, is dictated by the time its concentration remains within the therapeutic range. Dosing frequency, determined by the drug's rate of elimination, also influences the duration of a drug's action. More frequent dosing is required for rapidly eliminated drugs, and less frequent for those eliminated more slowly.

What is the role of dose size in reaching and maintaining the therapeutic range?

Dose size directly impacts how quickly the therapeutic range is reached and whether plasma concentration can be stabilized within it. Smaller doses reach the minimum effective concentration slower, but they do not exceed the maximum tolerated concentration, allowing plasma concentration to stabilize within the therapeutic window. Larger doses reach the MEC faster, but risk surpassing the MTC, potentially leading to toxicity.

What factors should be considered when determining drug dosing for a patient?

Individualization of dosing is essential to maintain plasma concentration within the therapeutic window. This is particularly true for drugs with a narrow therapeutic index, like digoxin and warfarin, for which therapeutic drug monitoring is required. The therapeutic index can be determined by dividing the dose causing toxicity in 50% of patients (TD50) by the dose producing a favorable response in 50% of patients (ED50). Besides pharmacokinetic factors, poor adherence to treatment might also be considered when assessing a patient for an unsatisfactory response to a drug.